MT 3724

Drug Profile

MT 3724

Alternative Names: MT3724

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecular Templates
  • Developer Banner MD Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Molecular Templates; University of Arizona; University of Texas M. D. Anderson Cancer Center
  • Class Antibodies; Antineoplastics; Bacterial toxins; Immunoconjugates
  • Mechanism of Action CD20 antigen inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 24 Oct 2017 Molecular Templates plans a phase II trial in Diffuse large B-cell lymphoma (Monotherapy, Second-line therapy or greater) in USA in 2018
  • 24 Oct 2017 Phase I trial in Diffuse large B cell lymphoma (Second-line therapy or greater, Monotherapy) in USA (IV)
  • 01 Apr 2017 Preclinical data presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top